$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Wall Street analysts project that BIOA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 42.20, with estimates ranging from a low of 23.00 to a high of 62.00.
The consensus 1-year price target stands at 42.20, with estimates ranging from a low of 23.00 to a high of 62.00.
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Significant contraction projected—major business challenges or industry disruption likely.
Limited coverage may indicate reduced institutional interest or information availability.
Moderate uncertainty in forecasts—typical for companies with evolving business models.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Significant contraction projected—major business challenges or industry disruption likely.
Limited coverage may indicate reduced institutional interest or information availability.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Limited coverage may indicate reduced institutional interest or information availability.
Mixed signals—some positive indicators offset by concerns about growth or uncertainty.
Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.
Significant contraction projected—major business challenges or industry disruption likely.
Limited coverage may indicate reduced institutional interest or information availability.
Analyst skepticism evident—carefully evaluate risks before investment decisions.
Limited coverage with volatile estimates: Few analysts covering despite significant projected changes may indicate information gaps or emerging risks.
During the last 12 months, insiders have purchased $583K and sold $1.63M worth of BIOA shares, resulting in $1.04M of net selling activity.
0
0.00
8.8K
157.08K
-157K
-$157K
0
0.00
49.3K
767.12K
-767K
-$767K
0
0.00
68.9K
701.91K
-702K
-$702K
132.0K
583.44K
0
0.00
+583K
+$583K
Enright Patrick G
Director
$98K
Garnier Jean Pierre
Director
$98K
Healy James
Director
$98K
Davidson Michael H.
Director
$98K
Hemrajani Rekha
Director
$98K
Rubin Paul D
Officer: Chief Medical Officer
$1.46M
Goldstein Dov A Md
Officer: Chief Financial Officer
$165K
Negative insider sentiment with $1.04M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
Continue your BIOA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.